News
Theatre contract for HCA Healthcare Harborne Hospital
Bender UK has announced that it has been awarded the contract to deliver critical power supply solutions and equip four state-of-the- art theatres at the new £100 million Harborne Hospital, part of HCA Healthcare UK. The multi-specialty private Hospital will include
50 private inpatient beds, 16 private day-case beds, and four state of the art operating theatres. It will offer modern outpatient services, including consultation rooms, an imaging suite, and a fully equipped day-case unit with outpatient chemotherapy and radiotherapy services. The Harborne Hospital is in partnership with University Hospitals Birmingham and will provide additional capacity for NHS patients on dedicated floors. Bender has installed resilient Medical IT Power
(IPS) across the hospital to support two endoscopy rooms, the six-bed Intensive Treatment Unit, and
the operating theatres. It is also supplying and commissioning equipment in the four theatres, including Bender CP9 theatre control panels, Merivaara Q-Flow advanced surgical lights, and full integration of audio-visual equipment, including HD cameras mounted within the lights and viewing screens. Multimovement ceiling-mounted service pendants will supply medical gases, power and data alongside the operating tables and intensive care beds. One of the theatres is a Hybrid Theatre where Bender is providing a complex medical technology integration system with third-party devices, including Siemens equipment. For more information on The Harborne Hospital
project, visit:
https://www.hcahealthcare.co.uk/facilities/ the-harborne-hospital
Sponsored by
New president announced for British Infection Association
A leading microbiologist and infection control expert at Sheffield Teaching Hospitals NHS Foundation Trust has become the President of the British Infection Association. Dr. David Partridge, Consultant Microbiologist and Infection Control Doctor at Sheffield Teaching Hospitals and Honorary Senior Lecturer at the Florey Institute, University of Sheffield, will serve as President of the Association for a two-year term. His appointment follows a two-year tenure as Vice-President. During COVID-19, David was part of an
international consortium of researchers that identified new variants of the SAR-CoV-2, and the virus responsible for COVID-19, using next generation genome sequencing techniques.
New white paper on IVDs anounced
IMed Consultancy, a regulatory and compliance consultancy provider, has launched a whitepaper on In-Vitro Diagnostics (IVDs). The paper analyses the key role of IVDs in supporting healthcare systems with early diagnosis to tackle common and rising diseases, and comes at a critical time for manufacturers that still have not started the process of registering legacy devices under the EU IVDR.
Views sought on new nurse pay scale
The government has published a call for evidence to seek views on a new pay scale for nurses. It will collate feedback from across the health sector on the merits of a separate pay structure for nursing staff in the NHS, considering both the risk and benefits of this approach. The government says that it has heard the concerns of nursing staff and their representatives about the challenges they face in terms of career progression and professional development. The call for evidence will seek to understand whether the Agenda for Change contract - covering more than one million NHS workers such as nurses, midwives and paramedics, as well as other non-medical, workers - is creating specific barriers to the career progression of nurses and
10
www.clinicalservicesjournal.com I February 2024
explore solutions that could be considered if the evidence shows there are issues with the current arrangements. Health Minister, Andrew Stephenson, said: “We
hugely value the work of nurses, who play a vital role in the NHS. We have listened to union concerns and are launching this call for evidence to explore the risks and benefits of a separate pay structure for nurses. I want stakeholders to share their expertise and help us collate feedback from across the healthcare sector, ultimately helping to make the NHS a better place to work.” This call for evidence, which runs for 12 weeks,
will now provide an opportunity for all stakeholders to share their views and suggestions. To have your say, visit:
http://tinyurl.com/28uxhsuv
IMed’s latest whitepaper (freely available at:
https://imedconsultancy.com) explores the role of IVDs and calls for suitable regulatory perspectives for their adoption in order to support increased market access. “The deadline to certify Class D devices under
the In-Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (‘IVDR’) is 26 May 2025. With estimates suggesting that the entire certification process for legacy products could take between 12 and 18 months, depending on risk class, status and maturity of the technical documentation and QMS, as well as the availability of a Notified Body, manufacturers need to act urgently to ensure they are not cut out of the market,” explains Jonathan Ripley, IVD and MD Consulting Services Director at IMed Consultancy. “Anecdotal evidence suggest that this deadline
has not been prioritised by far too many IVD manufacturers that now need to act swiftly if they want to provide continuity on the EU market for their products and their users.”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
